Docetaxel

Excerpt

Docetaxel, in combination with cisplatin, is approved by the Federal Drug Agency (FDA) as a first-line treatment for prostate cancer and is the standard of care for castration-resistant prostate cancer. The medication is effective in non–small cell lung cancer (NSCLC), particularly for patients with poor prognosis or metastatic disease, and is a standard adjunct in breast cancer treatment. Additionally, docetaxel is part of the TEX regimen for advanced gastric cancer and can be considered for stage IV NSCLC after previous therapies.